Search research articles
Contact Us
Filters
Showing results (1-10 of 68) with videos related to
Page
of 7
Sort By:
Expert Review of Clinical Pharmacology
|
December 25, 2014
Optimizing early Go/No Go decisions in CNS drug development
William Z Potter
Advances in Neurobiology
|
November 19, 2024
Public-Private Partnerships for Neuropsychiatric Drug Development: A Perspective
William Z Potter
Journal of Clinical Psychopharmacology
|
October 17, 2022
Better Approaches to Derisking Psychiatric Drug Development are Needed, Not New Funding Mechanisms
William Z Potter
The Journal of Clinical Investigation
|
August 28, 2012
Mining the secrets of the CSF: developing biomarkers of neurodegeneration
William Z Potter
Journal of Clinical Psychopharmacology
|
April 30, 2022
Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials
Margaret C Grabb, William Z Potter
Annual Review of Pharmacology and Toxicology
|
April 12, 2005
Biomarkers in psychotropic drug development: integration of data across multiple domains
Peter R Bieck, William Z Potter
Expert Opinion on Drug Discovery
|
December 7, 2013
Public-private partnerships to revitalize psychiatric drug discovery
Linda S Brady, William Z Potter
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
August 15, 2023
Finding new and better treatments for psychiatric disorders
Steven M Paul, William Z Potter
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 13, 2002
Biomarkers in psychotropic drug development
Saeeduddin Ahmed, P David Mozley, William Z Potter
Convulsive Therapy
|
January 1, 1987
Combined Lithium and Electroconvulsive Therapy: Pharmacokinetic and Pharmacodynamic Interactions
Matthew V. Rudorfer, Markku Linnoila, William Z. Potter
Page
of 7
Search research articles
Search
Showing results (1-10 of 68) with videos related to
Sort By:
Page
of 7
Expert Review of Clinical Pharmacology
|
December 25, 2014
Optimizing early Go/No Go decisions in CNS drug development
William Z Potter
Advances in Neurobiology
|
November 19, 2024
Public-Private Partnerships for Neuropsychiatric Drug Development: A Perspective
William Z Potter
Journal of Clinical Psychopharmacology
|
October 17, 2022
Better Approaches to Derisking Psychiatric Drug Development are Needed, Not New Funding Mechanisms
William Z Potter
The Journal of Clinical Investigation
|
August 28, 2012
Mining the secrets of the CSF: developing biomarkers of neurodegeneration
William Z Potter
Journal of Clinical Psychopharmacology
|
April 30, 2022
Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials
Margaret C Grabb, William Z Potter
Annual Review of Pharmacology and Toxicology
|
April 12, 2005
Biomarkers in psychotropic drug development: integration of data across multiple domains
Peter R Bieck, William Z Potter
Expert Opinion on Drug Discovery
|
December 7, 2013
Public-private partnerships to revitalize psychiatric drug discovery
Linda S Brady, William Z Potter
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
August 15, 2023
Finding new and better treatments for psychiatric disorders
Steven M Paul, William Z Potter
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 13, 2002
Biomarkers in psychotropic drug development
Saeeduddin Ahmed, P David Mozley, William Z Potter
Convulsive Therapy
|
January 1, 1987
Combined Lithium and Electroconvulsive Therapy: Pharmacokinetic and Pharmacodynamic Interactions
Matthew V. Rudorfer, Markku Linnoila, William Z. Potter
Page
of 7